Answers are grounded in this paper and cite their sources.
Bronchopulmonary dysplasia (BPD) affects over 15,000 infant births per year in the United States and is one of the major causes of mortality in preterm infants. BPD is one of the most common long-term adverse effects from premature infant birth. Unlike other medical complications related to premature infant birth, the incidence of BPD is not declining. Approximately 15 million infants are born prematurely each year. One million infants worldwide are reported to die each year as a result of medical complications due to premature birth. Therapeutic interventions for BPD include: maternal progesterone, antenatal steroids, surgical cerclage, decreased ventilation levels, caffeine/methylxanthines, diuretics, bronchodilators, postnatal steroids, vitamin A, and inhaled nitric oxide. These interventions have demonstrated limited effectiveness. Mesenchymal stem cells (MSCs) are the preferred source for therapy for infants with BPD as they differentiate into various cell types including: muscles, bones, fat, and cartilage. Stem cell transplantation has shown to improve lung function and repair, decrease pulmonary hypertension, decrease risk for neurodevelopmental disorders, decrease BPD severity, and increase survival rates. Researchers believe the use of stem cells may offer alternative options for patients with BPD to improve lung function and decrease complications related to premature birth. potential BMSCs in a hyperoxia-induced model of BPD in rats. Results showed chronic hyperoxia in newborn rats led to loss of lung capillaries, air space enlargement, and decreased resident lung BMSCs. Administration of BMSCs on postnatal day 4 revealed decreased alveolar and lung vascular injury, improved survival and exercise tolerance, and decreased pulmonary hypertension. suggested for of hUSMSCs at 10 days of life. Six infants received a low dose of hUSCMSCs and 6 infants received a high dose of hUSCMSCs. Results of the study revealed no significant clinical differences between low dose and high dose groups. The treatment was tolerated and appeared to be safe. Additional research was recommended with a larger randomized controlled blinded study This study will evaluate monitor long term outcomes of therapy using neurological development tests and growth measures and compare hUCMSCs intervention with a placebo group. Sixty-two premature infants with BPD have been enrolled in this study. Each infant received a single intratracheal administration of hUCMSCs. Follow up assessments will be completed at: 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 60 months. Several medical and clinical factors will be assessed and monitored: medical treatments including use of oxygen, steroids, bronchodilators, admissions to emergency room due to respiratory issues, survival rate, growth measured by percentile charts, neurological development measured by the Bayley Scale of Infant and Toddler Development, motor development measured by Gross Motor Function Classification System for Cerebral Palsy, incidence of deafness or blindness, number of adverse events, significant changes in physical exam, and brain MRI results. Patient data collection dates: January 2014 through March 2020. Clinical Trials.gov ID NCT01897987 3+3+3
No takes yet. Share an insight, caveat, or question.
Andrews et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: